Manuscripts
Showing 45 manuscripts.
Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling
Citation
Angela Colbers, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, José Moltó, Mark Mirochnick, Mats O Karlsson, David M Burger, Stein Schalkwijk, Rob Ter Heine. Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. Journal of Antimicrobial Chemotherapy. 2019. 74: 1348-1356. PMID: 30715324Year
2019
Journal
Journal of Antimicrobial Chemotherapy
Study
P1026S
Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum
Citation
Brookie M Best, Alice M Stek, Edmund V Capparelli, IMPAACT P1026s Protocol Team, Ahizechukwu C Eke, Angela Kashuba, Craig Sykes, Jiajia Wang, Elizabeth Smith, Samantha Calabrese, Mark Mirochnick, Nahida Chakhtoura. Rilpivirine Plasma and Cervicovaginal Concentrations in Women During Pregnancy and Postpartum. Journal of Acquired Immune Deficiency Syndromes. 2018. 78: 308-313. PMID: 29528944Year
2018
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1026S
Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV
Citation
Edmund V Capparelli, Alice Stek, Shelley L Buschur, Edward P Acosta, IMPAACT P1026s Protocol Team, Brookie M Best, Jiajia Wang, Emily Barr, Elizabeth Smith, Nahida Chakhtoura, Sandra Burchett, Mark Mirochnick, Nikki Mulligan. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018. 32: 729-737. PMID: 2969162Year
2018
Journal
AIDS
Study
P1026S
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV
Citation
Jiajia Wang, Edmund V Capparelli, Alice Stek, Emily Barr, Martina L Badell, Edward P Acosta, Murli Purswani, Elizabeth Smith, Nahida Chakhtoura, Kyunghun Park, Sandra Burchett, David E Shapiro, Mark Mirochnick, Jeremiah D Momper, Brookie M Best, IMPAACT P1026s Protocol Team. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018. 32: 2507-2516. PMID: 30134297Year
2018
Journal
AIDS
Study
P1026S
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
Citation
Angela C Colbers, Alwin D R Huitema, Paolo Denti, Kelly E Dooley, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, Mark Mirochnick, David M Burger, Stein Schalkwijk, Rob Ter Heine. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clinical Pharmacokinetics. 2018. 57: 1421-1433. PMID: 29520730Year
2018
Journal
Clinical Pharmacokinetics
Study
P1026S
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women
Citation
Mark Mirochnick, IMPAACT P1026s Protocol Team, Edmund V. Capparelli, Alice Stek, Jiajia Wang, Sandra K. Burchett, Regis Kreitchmann, Kittipong Rungruengthanakit, Kathleen George, Tim R. Cressey, Nahida Chakhtoura, Elizabeth Smith, David E. Shapiro, Anna Tran, Brookie M. Best. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women. Journal of Acquired Immune Deficiency Syndromes. 2016. 72: 289-96. PMID: 26918544Year
2016
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1026S
Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
Citation
Brookie M Best, Edmund V Capparelli, Alice M Stek, Courtney V Fletcher, Angela Colbers, Jiajia Wang, Jose Molto, Graham Taylor, Elizabeth Smith, Carmen Hidalgo Tenorio, Nahida Chakhtoura, Marjo Van Kasteren, Mark Mirochnick, David Burger, Nikki Mulligan, Stein Schalkwijk. Etravirine Pharmacokinetics in HIV-Infected Pregnant Women. Frontiers in Pharmacology. 2016. 7: 239. PMID: 27540363Year
2016
Journal
Frontiers in Pharmacology
Study
P1026S
Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics
Citation
L Huang, BM Best, A Stek, P Lizak, SK Burchett, JS Read, H Watts, M Mirochnick, EV Capparelli, IMPAACT P1026s Protocol Team, FT Aweeka, C Hu. Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Medicine. 2015. 16: 176-183. PMID: 25407158Year
2015
Journal
HIV Medicine
Study
P1026S, P1026S
Pharmacokinetics of tenofovir during pregnancy and postpartum
Citation
H Li, A Stek, C Hu, J Wang, E Hawkins, M Byroads, DH Watts, E Smith, CV Fletcher, EV Capparelli, M Mirochnick, IMPAACT P1026s Team, BM Best, S Burchett. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Medicine. 2015. 16: 502-511. PMID: 25959631Year
2015
Journal
HIV Medicine
Study
P1026S, P1026S
Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women
Citation
Kabamba Kabeya, Mark Mirochnick, PANNA network and the IMPAACT 1026s study team, Jiajia Wang, Elizabeth Smith, Stein Schalkwijk, Alice Stek, Carmen Hidalgo Tenorio, David Hawkins, Graham Taylor, Regis Kreitchmann, Sandra Burchett, Annette Haberl, Marjo van Kasteren, Edmund Capparelli, David Burger, Angela Colbers, Brookie Best. Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. Clinical Infectious Diseases. 2015. 61: 1582-1589. PMID: 26202768Year
2015
Journal
Clinical Infectious Diseases
Study
P1026S